March 30, 2017 — Analogic Corp. announced that it will introduce its bkFusion solution for improving biopsy targeting in prostate cancer, at the 32nd Annual European Association of Urology (EAU) Congress, March 24–27 in London.
bkFusion is the latest innovation from the company’s flagship BK Ultrasound brand. It is the first magnetic resonance (MR)-fusion prostate biopsy application that is fully integrated onto a premium ultrasound system — the bk3000 — for use by urologists in both hospital and office settings. The bk3000 system is designed for urology, general imaging and procedure guidance applications.
Systematic biopsies do not always give enough information to be conclusive. bkFusion seamlessly overlays MR image information about lesion location and extent onto real-time ultrasound images, without the need for an additional workstation. This improves workflow and minimizes the system’s footprint, which are significant benefits for the urologist performing biopsies in the office, enabling faster and more reliable disease management.
BK Ultrasound, powered by Analogic, has partnered with MIM Software Inc. to create bkFusion. MIM is a provider of imaging solutions for radiation oncology, radiology, nuclear medicine, neuroimaging and cardiac imaging. This software builds on MIM’s Predictive Fusion technology to enable the urologist to precisely biopsy MR-defined targets quickly and accurately. With its small footprint, the bk3000 fits easily into any office space and, because bkFusion is completely integrated on the ultrasound system, no additional bulky equipment or set-up time is required. The bkFusion system communicates easily with radiology departments, accessing the MR images via picture archiving and communication system (PACS) or a secure cloud platform.
For more information: www.bkultrasound.com
April 24, 2024 
